<div class="mw-parser-output"><table class="infobox" style="width:22em">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background:#ccc">Gaucher's disease</th>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#eee;;">Classification and external resources</th>
</tr>
<tr>
<th scope="row"><a href="/wiki/Specialty_(medicine)" title="Specialty (medicine)">Specialty</a></th>
<td><span><span><a href="/wiki/Endocrinology" title="Endocrinology">endocrinology</a></span></span></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2016/en#/E75.2">E75.2</a> (<a href="/wiki/ILDS" class="mw-redirect" title="ILDS">ILDS</a> E75.220)</td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9-CM</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=272.7">272.7</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/OMIM" class="mw-redirect" title="OMIM">OMIM</a></th>
<td><a rel="nofollow" class="external text" href="https://omim.org/entry/230800">230800</a> <a rel="nofollow" class="external text" href="https://omim.org/entry/230900">230900</a> <a rel="nofollow" class="external text" href="https://omim.org/entry/231000">231000</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb5124.htm">5124</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="https://medlineplus.gov/ency/article/000564.htm">000564</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/ped/topic837.htm">ped/837</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/derm/topic709.htm#">derm/709</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Patient_UK" title="Patient UK">Patient UK</a></th>
<td><a rel="nofollow" class="external text" href="http://patient.info/doctor/gauchers-disease-pro">Gaucher's disease</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="//www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&amp;term=D005776">D005776</a></td>
</tr>
<tr class="noprint">
<td colspan="2" style="text-align:center">
<div style="text-align: right; font-size:0.9em;">[<a href="https://www.wikidata.org/wiki/Q861645" class="extiw" title="d:Q861645">edit on Wikidata</a>]</div>
</td>
</tr>
</table>
<p><b>Gaucher's disease</b> (<small>pronounced&#160;</small><span class="nowrap"><span title="Representation in the International Phonetic Alphabet (IPA)" class="IPA"><a href="/wiki/Help:IPA/English" title="Help:IPA/English">/goʊˈʃeɪz dɨziːz/</a></span></span><i><small><sup>&#160;(deprecated template)</sup></small></i>) is the most common of the <a href="/wiki/Lysosomal_storage_disease" title="Lysosomal storage disease">lysosomal storage diseases</a>. It is caused by a deficiency of the enzyme <a href="/wiki/Glucocerebrosidase" title="Glucocerebrosidase">glucocerebrosidase</a>, leading to an accumulation of its substrate, the fatty substance <a href="/wiki/Cerebroside" title="Cerebroside">glucocerebroside</a> (also known as <a href="/wiki/Glucosylceramide" class="mw-redirect" title="Glucosylceramide">glucosylceramide</a>). Fatty material can collect in the <a href="/wiki/Spleen" title="Spleen">spleen</a>, liver, <a href="/wiki/Kidney" title="Kidney">kidneys</a>, <a href="/wiki/Lung" title="Lung">lungs</a>, <a href="/wiki/Brain" title="Brain">brain</a> and bone marrow. Symptoms may include enlarged spleen and liver, liver malfunction, <a href="/wiki/List_of_skeletal_disorders" class="mw-redirect" title="List of skeletal disorders">skeletal disorders</a> and bone lesions that may be painful, severe <a href="/wiki/Neurology" title="Neurology">neurologic</a> complications, swelling of <a href="/wiki/Lymph_node" title="Lymph node">lymph nodes</a> and (occasionally) adjacent joints, distended abdomen, a brownish tint to the skin, <a href="/wiki/Anemia" title="Anemia">anemia</a>, low blood <a href="/wiki/Platelet" title="Platelet">platelets</a> and yellow fatty deposits on the <a href="/wiki/Sclera" title="Sclera">sclera</a>. Persons affected most seriously may also be more susceptible to infection. The disease shows <a href="/wiki/Autosomal_recessive" class="mw-redirect" title="Autosomal recessive">autosomal recessive</a> inheritance and therefore affects both males and females. It is <a href="/wiki/Eponym" title="Eponym">named after</a> the French doctor <a href="/wiki/Philippe_Gaucher" title="Philippe Gaucher">Philippe Gaucher</a> who originally described it in 1882. <sup id="cite_ref-1" class="reference"><a href="#cite_note-1">[1]</a></sup> The biochemical basis for the disease would be elucidated in <a href="/wiki/1965" title="1965">1965</a> by Brady <i>et al</i>.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2">[2]</a></sup> The first effective treatment for the disease, the drug Ceredase, was approved by the FDA in June 1995. An improved drug, Cerezyme, was approved by the FDA in 2001 and has replaced the use of Ceredase.</p>
<p><br /></p>
<p></p>
<div id="toc" class="toc">
<div class="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Subtypes"><span class="tocnumber">1</span> <span class="toctext">Subtypes</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Signs_and_symptoms"><span class="tocnumber">2</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Diagnosis"><span class="tocnumber">3</span> <span class="toctext">Diagnosis</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Pathophysiology"><span class="tocnumber">4</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Classification_and_genetics"><span class="tocnumber">5</span> <span class="toctext">Classification and genetics</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Epidemiology"><span class="tocnumber">6</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-7"><a href="#Treatment"><span class="tocnumber">7</span> <span class="toctext">Treatment</span></a></li>
<li class="toclevel-1 tocsection-8"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-9"><a href="#External_links"><span class="tocnumber">9</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Subtypes">Subtypes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=1" title="Edit section: Subtypes">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Gaucher's disease has three common clinical subtypes.</p>
<ul>
<li>Type I (or nonneuropathic type) is the most common form of the disease, occurring in approximately 1 in 50,000 live births. It occurs most often among persons of <a href="/wiki/Ashkenazi_Jews" title="Ashkenazi Jews">Ashkenazi Jewish</a> heritage. Symptoms may begin early in life or in adulthood and include <a href="/wiki/Hepatomegaly" title="Hepatomegaly">enlarged liver</a> and grossly <a href="/wiki/Splenomegaly" title="Splenomegaly">enlarged spleen</a> (together <a href="/wiki/Hepatosplenomegaly" title="Hepatosplenomegaly">hepatosplenomegaly</a>); the spleen can rupture and cause additional complications. Skeletal weakness and bone disease may be extensive. Spleen enlargement and bone marrow replacement cause <a href="/wiki/Anemia" title="Anemia">anemia</a>, thrombocytopenia and <a href="/wiki/Leukopenia" title="Leukopenia">leukopenia</a>. The brain is not affected, but there may be lung and, rarely, kidney impairment. Patients in this group usually <a href="/wiki/Bruise" title="Bruise">bruise</a> easily and experience fatigue due to low blood platelets. Depending on disease onset and severity, type 1 patients may live well into adulthood. Many patients have a mild form of the disease or may not show any symptoms.</li>
</ul>
<ul>
<li>Type II (or acute infantile neuropathic Gaucher's disease) typically begins within 6 months of birth and has an incidence rate of approximately 1 in 100,000 live births. Symptoms include an enlarged liver and spleen, extensive and progressive brain damage, eye movement disorders, <a href="/wiki/Spasticity" title="Spasticity">spasticity</a>, <a href="/wiki/Seizure" class="mw-redirect" title="Seizure">seizures</a>, limb rigidity, and a poor ability to suck and swallow. Affected children usually die by age 2.</li>
</ul>
<ul>
<li>Type III (the chronic neuropathic form) can begin at any time in childhood or even in adulthood, and occurs in approximately 1 in 100,000 live births. It is characterized by slowly progressive but milder neurologic symptoms compared to the acute or type 2 version. Major symptoms include an enlarged spleen and/or liver, seizures, poor coordination, skeletal irregularities, eye movement disorders, blood disorders including anemia and respiratory problems. Patients often live into their early teen years and adulthood.</li>
</ul>
<p>These subtypes have come under some criticism for not taking account of the spectrum of observable symptoms (the <a href="/wiki/Phenotypes" class="mw-redirect" title="Phenotypes">phenotypes</a>.<a rel="nofollow" class="external autonumber" href="http://www.gaucher.org.uk/consenmarch2002.htm">[1]</a>) There are also compound heterozygous variations which considerably increase the complexity of predicting disease course.</p>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=2" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li>Painless <a href="/wiki/Hepatomegaly" title="Hepatomegaly">hepatomegaly</a> and <a href="/wiki/Splenomegaly" title="Splenomegaly">splenomegaly</a>; the size of the spleen can be 1500-3000 ml, as opposed to the normal size of 50-200 ml.</li>
<li><a href="/wiki/Hypersplenism" class="mw-redirect" title="Hypersplenism">Hypersplenism</a>: the rapid and premature destruction of blood cells, leading to <a href="/wiki/Anemia" title="Anemia">anemia</a>, <a href="/wiki/Neutropenia" title="Neutropenia">neutropenia</a> and <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a> (with an increased risk of <a href="/wiki/Infection" title="Infection">infection</a> and <a href="/wiki/Bleeding" title="Bleeding">bleeding</a>)</li>
<li><a href="/wiki/Cirrhosis" title="Cirrhosis">Cirrhosis</a> of the liver is rare</li>
<li><a href="/wiki/Neurology" title="Neurology">Neurological</a> symptoms occur only in some types of Gaucher's (see below):
<ul>
<li>Type II: serious convulsions, hypertonia, mental retardation, apnea.</li>
<li>Type III: muscle twitches known as <a href="/wiki/Myoclonus" title="Myoclonus">myoclonus</a>, convulsions, dementia, ocular muscle apraxia.</li>
</ul>
</li>
<li><a href="/wiki/Osteoporosis" title="Osteoporosis">Osteoporosis</a>: 75% develop visible bony abnormalities due to the accumulated glucosylceramide. A deformity of the distal <a href="/wiki/Femur" title="Femur">femur</a> in the shape of an <a href="/wiki/Erlenmeyer_flask" title="Erlenmeyer flask">Erlenmeyer flask</a> is commonly described.</li>
<li>Yellowish-brown skin <a href="/wiki/Pigmentation" class="mw-redirect" title="Pigmentation">pigmentation</a></li>
</ul>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=3" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>A definitive diagnosis is made with <a href="/wiki/Genetic_test" class="mw-redirect" title="Genetic test">genetic testing</a>. As there are numerous different mutations, sequencing of the beta-glucosidase gene is sometimes necessary to confirm the diagnosis. Prenatal diagnosis is available, and is useful when there is a known genetic risk factor.</p>
<p>A diagnosis can also be implied by biochemical abnormalities such as high <a href="/wiki/Alkaline_phosphatase" title="Alkaline phosphatase">alkaline phosphatase</a>, <a href="/wiki/Angiotensin-converting_enzyme" title="Angiotensin-converting enzyme">angiotensin-converting enzyme</a> (ACE) and <a href="/wiki/Immunoglobulin" class="mw-redirect" title="Immunoglobulin">immunoglobulin</a> levels, or by cell analysis showing "crinkled paper" cytoplasm and glycolipid-laden macrophages.</p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=4" title="Edit section: Pathophysiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:311px;"><a href="/wiki/File:Acid_beta_glucosidase.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/e/e2/Acid_beta_glucosidase.png" width="309" height="377" class="thumbimage" data-file-width="309" data-file-height="377" /></a>
<div class="thumbcaption">Acid beta-glucosidase</div>
</div>
</div>
<p>The disease is caused by a defect in the <a href="/wiki/Housekeeping_gene" title="Housekeeping gene">housekeeping gene</a> <i>lysosomal gluco-cerebrosidase</i> (also known as beta-glucosidase, <a href="/wiki/Enzyme_Commission_number" title="Enzyme Commission number">EC</a> <a rel="nofollow" class="external text" href="http://enzyme.expasy.org/EC/3.2.1.45">3.2.1.45</a>, <span class="plainlinks"><a href="/wiki/Protein_Data_Bank" title="Protein Data Bank">PDB</a>: <a rel="nofollow" class="external text" href="http://www.rcsb.org/pdb/explore/explore.do?structureId=1OGS">1OGS</a></span>​) on the first <a href="/wiki/Chromosome" title="Chromosome">chromosome</a> (1q21). The <a href="/wiki/Enzyme" title="Enzyme">enzyme</a> is a 55.6 <a href="/wiki/Kilodalton" class="mw-redirect" title="Kilodalton">KD</a>, 497 <a href="/wiki/Amino_acid" title="Amino acid">amino acids</a> long protein that catalyses the breakdown of <a href="/wiki/Glucocerebroside" title="Glucocerebroside">glucocerebroside</a>, a <a href="/wiki/Cell_membrane" title="Cell membrane">cell membrane</a> constituent of red and white blood cells. The <a href="/wiki/Macrophage" title="Macrophage">macrophages</a> that clear these cells are unable to eliminate the waste product, which accumulates in fibrils, and turn into <i>Gaucher cells</i>, which appear on <a href="/wiki/Light_microscopy" class="mw-redirect" title="Light microscopy">light microscopy</a> to resemble crumpled-up paper.</p>
<p>Different mutations in the beta-glucosidase determine the remaining activity of the enzyme, and, to a large extent, the <a href="/wiki/Phenotype" title="Phenotype">phenotype</a>.</p>
<p>In the brain (type II and III), glucocerebroside accumulates due to the turnover of complex <a href="/wiki/Lipid" title="Lipid">lipids</a> during brain development and the formation of the <a href="/wiki/Myelin_sheath" class="mw-redirect" title="Myelin sheath">myelin sheath</a> of nerves.</p>
<p>Research suggests that heterozygotes for particular acid beta-glucosidase mutations are at an increased risk of <a href="/wiki/Parkinson%27s_disease" title="Parkinson's disease">Parkinson's disease</a>.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3">[3]</a></sup> A study of 1525 Gaucher patients in the <a href="/wiki/United_States" title="United States">United States</a> suggested that while cancer risk is not elevated, particular malignancies (<a href="/wiki/Non-Hodgkin_lymphoma" title="Non-Hodgkin lymphoma">non-Hodgkin lymphoma</a>, <a href="/wiki/Melanoma" title="Melanoma">melanoma</a> and <a href="/wiki/Pancreatic_cancer" title="Pancreatic cancer">pancreatic cancer</a>) occurred at a 2-3 times higher rate.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4">[4]</a></sup></p>
<h2><span class="mw-headline" id="Classification_and_genetics">Classification and genetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=5" title="Edit section: Classification and genetics">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The three types of Gaucher's disease are inherited in an <a href="/wiki/Autosomal_recessive" class="mw-redirect" title="Autosomal recessive">autosomal recessive</a> fashion. Both parents must be carriers in order for a child to be affected. If both parents are carriers, there is a one in four, or 25%, chance with each pregnancy for an affected child. <a href="/wiki/Genetic_counseling" title="Genetic counseling">Genetic counseling</a> and <a href="/wiki/Genetic_testing" title="Genetic testing">genetic testing</a> is recommended for families who may be carriers of mutations.</p>
<p>Each type has been linked to particular mutations. In all, there are about 80 known mutations, grouped into three main types:<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">[5]</a></sup></p>
<ul>
<li>Type I (N370S <a href="/wiki/Homozygote" class="mw-redirect" title="Homozygote">homozygote</a>), the most common, also called the "non-neuropathic" type occurs mainly in <a href="/wiki/Ashkenazi" class="mw-redirect" title="Ashkenazi">Ashkenazi Jews</a>, at 100 times the occurence in the general populace. The median age at diagnosis is 28 years of age,<sup id="cite_ref-Grabowski2008_6-0" class="reference"><a href="#cite_note-Grabowski2008-6">[6]</a></sup> and life expectancy is mildly decreased. There are no neurological symptoms.</li>
<li>Type II (1 or 2 <a href="/wiki/Allele" title="Allele">alleles</a> L444P) is characterized by neurological problems in small children. The enzyme is hardly released into the <a href="/wiki/Lysosome" title="Lysosome">lysosomes</a>. Prognosis is dismal: most die before reaching the third birthday.</li>
<li>Type III (also 1-2 copies of L444P, possibly delayed by protective polymorphisms) occurs in <a href="/wiki/Sweden" title="Sweden">Swedish</a> patients from the <a href="/wiki/Norrbotten" title="Norrbotten">Norrbotten</a> region. This group develops the disease somewhat later, but most die before their 30th birthday.</li>
</ul>
<p>Diaz <i>et al</i> suggest that the Gaucher-causing mutations entered the Ashkenazi Jewish gene pool in the early Middle Ages (48-55 generations ago).<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">[7]</a></sup></p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=6" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li>The National Gaucher Foundation states that around 1 in 100 people in the general U.S. population is a carrier for type 1 Gaucher's disease, giving a prevalence of 1 in 40,000: among <a href="/wiki/Ashkenazi_Jew" class="mw-redirect" title="Ashkenazi Jew">Ashkenazi Jews</a> the rate of carriers is considerably higher, at roughly 1 in 15.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8">[8]</a></sup></li>
<li>Type 2 Gaucher's disease shows no particular preference for any ethnic group.</li>
<li>Type 3 Gaucher's disease is especially common in the population of the Northern Swedish region of <a href="/wiki/Norrbotten" title="Norrbotten">Norrbotten</a> where the incidence of the disease is 1 in 50,000.</li>
</ul>
<h2><span class="mw-headline" id="Treatment">Treatment</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=7" title="Edit section: Treatment">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>For type 1 and most type 3 patients, <a href="/wiki/Enzyme_replacement_treatment" class="mw-redirect" title="Enzyme replacement treatment">enzyme replacement treatment</a> with <a href="/wiki/Intravenous" class="mw-redirect" title="Intravenous">intravenous</a> <a href="/wiki/Recombinant_DNA" title="Recombinant DNA">recombinant</a> glucocerebrosidase can dramatically decrease <a href="/wiki/Liver" title="Liver">liver</a> and <a href="/wiki/Spleen" title="Spleen">spleen</a> size, reduce skeletal abnormalities, and reverse other manifestations. The rarity of the disease means that dose-finding studies have been difficult to conduct, so there remains controversy over the optimal dose and dosing frequency.<sup id="cite_ref-Grabowski2008_6-1" class="reference"><a href="#cite_note-Grabowski2008-6">[6]</a></sup> Due to the low incidence, this has become an <a href="/wiki/Orphan_drug" title="Orphan drug">orphan drug</a> in many countries, meaning that a government recognizes and accomodates the financial constraints that limit research into drugs that address a small population.</p>
<p>Successful <a href="/wiki/Bone_marrow_transplantation" class="mw-redirect" title="Bone marrow transplantation">bone marrow transplantation</a> cures the non-neurological manifestations of the disease, because it introduces a <a href="/wiki/Monocyte" title="Monocyte">monocyte</a> population with active beta-glucosidase. However, this procedure carries significant risk and is rarely performed in Gaucher patients. Surgery to remove the spleen (<a href="/wiki/Splenectomy" title="Splenectomy">splenectomy</a>) may be required on rare occasions if the patient is anemic or when the enlarged organ affects the patient’s comfort. <a href="/wiki/Blood_transfusion" title="Blood transfusion">Blood transfusion</a> may benefit some anemic patients. Other patients may require <a href="/wiki/Replacement_joint" class="mw-redirect" title="Replacement joint">joint replacement</a> surgery to improve mobility and quality of life. Other treatment options include <a href="/wiki/Antibiotic" class="mw-redirect" title="Antibiotic">antibiotics</a> for <a href="/wiki/Infection" title="Infection">infections</a>, <a href="/wiki/Antiepileptic" class="mw-redirect" title="Antiepileptic">antiepileptics</a> for seizures, bisphosphonates for bone lesions, and <a href="/wiki/Liver_transplant" class="mw-redirect" title="Liver transplant">liver transplants</a>. Substrate reduction therapy may prove to be effective in stopping Type 2, as it can cross through the blood barrier into the brain. There is currently no effective treatment for the severe brain damage that may occur in patients with types 2 and 3 Gaucher disease. <a href="/wiki/Gene_therapy" title="Gene therapy">Gene therapy</a> may be a future step.</p>
<p>Gaucher's disease has recently become a target for more than one effort at <a href="/wiki/Pharmacological_chaperone" title="Pharmacological chaperone">pharmacological chaperoning</a>, which involves the use of orally administered drugs that operate at a molecular level.</p>
<p>The currently existing treatment of Gaucher's disease, Cerezyme (<a href="/wiki/Imiglucerase" title="Imiglucerase">imiglucerase</a> for injection), costs up to $550,000 annually for a single patient and the treatment should be continued for life. This recombinant beta-glucosidase is given intravenously. <a href="/wiki/Miglustat" title="Miglustat">Miglustat</a> is another drug approved for this disease in 2003.</p>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=8" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text">Gaucher PCE. <i>De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie</i>. Academic thesis, Paris, France, 1882.</span></li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><cite class="citation journal">Brady RO, Kanfer JN, Shapiro D (1965). "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease". <i>Biochem. Biophys. Res. Commun</i>. <b>18</b>: 221–5. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14282020">14282020</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2F0006-291X%2865%2990743-6">10.1016/0006-291X(65)90743-6</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGaucher%27s+disease&amp;rft.atitle=Metabolism+of+glucocerebrosides.+II.+Evidence+of+an+enzymatic+deficiency+in+Gaucher%27s+disease&amp;rft.au=Brady+RO%2C+Kanfer+JN%2C+Shapiro+D&amp;rft.date=1965&amp;rft.genre=article&amp;rft.jtitle=Biochem.+Biophys.+Res.+Commun.&amp;rft.pages=221-5&amp;rft.volume=18&amp;rft_id=info%3Adoi%2F10.1016%2F0006-291X%2865%2990743-6&amp;rft_id=info%3Apmid%2F14282020&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span><span class="citation-comment" style="display:none; color:#33aa33; margin-left:0.3em">CS1 maint: Multiple names: authors list (<a href="/wiki/Category:CS1_maint:_Multiple_names:_authors_list" title="Category:CS1 maint: Multiple names: authors list">link</a>)</span></span></li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><cite class="citation journal">Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004). "Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews". <i>N. Engl. J. Med</i>. <b>351</b> (19): 1972–7. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15525722">15525722</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1056%2FNEJMoa033277">10.1056/NEJMoa033277</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGaucher%27s+disease&amp;rft.atitle=Mutations+in+the+glucocerebrosidase+gene+and+Parkinson%27s+disease+in+Ashkenazi+Jews&amp;rft.au=Aharon-Peretz+J%2C+Rosenbaum+H%2C+Gershoni-Baruch+R&amp;rft.date=2004&amp;rft.genre=article&amp;rft.issue=19&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1972-7&amp;rft.volume=351&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa033277&amp;rft_id=info%3Apmid%2F15525722&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span><span class="citation-comment" style="display:none; color:#33aa33; margin-left:0.3em">CS1 maint: Multiple names: authors list (<a href="/wiki/Category:CS1_maint:_Multiple_names:_authors_list" title="Category:CS1 maint: Multiple names: authors list">link</a>)</span></span></li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><cite class="citation journal">Landgren O, Turesson I, Gridley G, Caporaso NE (2007). "Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease". <i>Archives of Internal Medicine</i>. <b>167</b> (11): 1189–1194. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17563029">17563029</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1001%2Farchinte.167.11.1189">10.1001/archinte.167.11.1189</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGaucher%27s+disease&amp;rft.atitle=Risk+of+Malignant+Disease+Among+1525+Adult+Male+US+Veterans+With+Gaucher+Disease&amp;rft.au=Landgren+O%2C+Turesson+I%2C+Gridley+G%2C+Caporaso+NE&amp;rft.date=2007&amp;rft.genre=article&amp;rft.issue=11&amp;rft.jtitle=Archives+of+Internal+Medicine&amp;rft.pages=1189-1194&amp;rft.volume=167&amp;rft_id=info%3Adoi%2F10.1001%2Farchinte.167.11.1189&amp;rft_id=info%3Apmid%2F17563029&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span><span class="citation-comment" style="display:none; color:#33aa33; margin-left:0.3em">CS1 maint: Multiple names: authors list (<a href="/wiki/Category:CS1_maint:_Multiple_names:_authors_list" title="Category:CS1 maint: Multiple names: authors list">link</a>)</span></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><a href="/wiki/Online_Mendelian_Inheritance_in_Man" title="Online Mendelian Inheritance in Man">Online Mendelian Inheritance in Man</a> (OMIM) <a rel="nofollow" class="external text" href="https://omim.org/entry/606463">606463</a></span></li>
<li id="cite_note-Grabowski2008-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-Grabowski2008_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Grabowski2008_6-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Grabowski GA (2008). "Phenotype, diagnosis, and treatment of Gaucher's disease". <i>Lancet</i>. <b>372</b>: 1263–1271. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2FS0140-6736%2808%2961522-6">10.1016/S0140-6736(08)61522-6</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGaucher%27s+disease&amp;rft.atitle=Phenotype%2C+diagnosis%2C+and+treatment+of+Gaucher%27s+disease&amp;rft.au=Grabowski+GA&amp;rft.date=2008&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.pages=1263-1271&amp;rft.volume=372&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2808%2961522-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation journal">Diaz GA, Gelb BD, Risch N; et al. (2000). "Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations". <i>Am. J. Hum. Genet</i>. <b>66</b> (6): 1821–32. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10777718">10777718</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1086%2F302946">10.1086/302946</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGaucher%27s+disease&amp;rft.atitle=Gaucher+disease%3A+the+origins+of+the+Ashkenazi+Jewish+N370S+and+84GG+acid+beta-glucosidase+mutations&amp;rft.au=Diaz+GA%2C+Gelb+BD%2C+Risch+N&amp;rft.date=2000&amp;rft.genre=article&amp;rft.issue=6&amp;rft.jtitle=Am.+J.+Hum.+Genet.&amp;rft.pages=1821-32&amp;rft.volume=66&amp;rft_id=info%3Adoi%2F10.1086%2F302946&amp;rft_id=info%3Apmid%2F10777718&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span><span class="citation-comment" style="display:none; color:#33aa33; margin-left:0.3em">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)CS1 maint: Multiple names: authors list (<a href="/wiki/Category:CS1_maint:_Multiple_names:_authors_list" title="Category:CS1 maint: Multiple names: authors list">link</a>)</span></span></li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.gaucherdisease.org/prevalence.php">"National Gaucher Foundation"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2007-05-30</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGaucher%27s+disease&amp;rft.btitle=National+Gaucher+Foundation&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.gaucherdisease.org%2Fprevalence.php&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Gaucher%27s_disease&amp;action=edit&amp;section=9" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><i><a rel="nofollow" class="external text" href="https://www.ninds.nih.gov/Disorders/All-Disorders/gauchers-Information-Page">gauchers</a></i> at <a href="/wiki/National_Institute_of_Neurological_Disorders_and_Stroke" title="National Institute of Neurological Disorders and Stroke">NINDS</a></li>
<li><a rel="nofollow" class="external text" href="http://www.gaucher.org.uk/index.htm">Gauchers News</a></li>
<li><a rel="nofollow" class="external text" href="http://www.gaucher.org.uk/ega/alliance.htm">European Gaucher Alliance</a></li>
<li><a rel="nofollow" class="external text" href="http://www.gaucherdisease.org">National Gaucher Foundation</a></li>
</ul>
<div role="navigation" class="navbox" aria-labelledby=".28LSD.29_Inborn_error_of_lipid_metabolism:_lipid_storage_disorders_.28E75.2C_272.7.E2.80.93272.8.29" style="padding:3px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Lipid_storage_disorders" title="Template:Lipid storage disorders"><abbr title="View this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Lipid_storage_disorders" title="Template talk:Lipid storage disorders"><abbr title="Discuss this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Lipid_storage_disorders&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none;">e</abbr></a></li>
</ul>
</div>
<div id=".28LSD.29_Inborn_error_of_lipid_metabolism:_lipid_storage_disorders_.28E75.2C_272.7.E2.80.93272.8.29" style="font-size:114%;margin:0 4em">(<a href="/wiki/Lysosomal_storage_disease" title="Lysosomal storage disease">LSD</a>) <a href="/wiki/Inborn_error_of_metabolism" title="Inborn error of metabolism">Inborn error</a> of <a href="/wiki/Inborn_error_of_lipid_metabolism" title="Inborn error of lipid metabolism">lipid metabolism</a>: <a href="/wiki/Lipid_storage_disorder" title="Lipid storage disorder">lipid storage disorders</a> (<a href="/wiki/ICD-10_Chapter_IV:_Endocrine,_nutritional_and_metabolic_diseases#.28E75.29_Lipids" title="ICD-10 Chapter IV: Endocrine, nutritional and metabolic diseases">E75</a>, <a href="/wiki/List_of_ICD-9_codes_240%E2%80%93279:_endocrine,_nutritional_and_metabolic_diseases,_and_immunity_disorders#Other_metabolic_and_immunity_disorders_.28270.E2.80.93279.29" title="List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders">272.7–272.8</a>)</div>
</th>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Sphingolipidoses" title="Sphingolipidoses">Sphingolipidoses</a><br />
(to <a href="/wiki/Ceramide" title="Ceramide">ceramide</a>)</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:1%">From <a href="/wiki/Ganglioside" title="Ganglioside">ganglioside</a><br />
(<a href="/wiki/Gangliosidosis" title="Gangliosidosis">gangliosidoses</a>)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Ganglioside" title="Ganglioside">Ganglioside</a>: <a href="/wiki/GM1_gangliosidoses" title="GM1 gangliosidoses">GM1 gangliosidoses</a></li>
<li><a href="/wiki/GM2_gangliosidoses" title="GM2 gangliosidoses">GM2 gangliosidoses</a> (<a href="/wiki/Sandhoff_disease" title="Sandhoff disease">Sandhoff disease</a></li>
<li><a href="/wiki/Tay%E2%80%93Sachs_disease" title="Tay–Sachs disease">Tay–Sachs disease</a></li>
<li><a href="/wiki/GM2-gangliosidosis,_AB_variant" title="GM2-gangliosidosis, AB variant">AB variant</a>)</li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:1%">From <a href="/wiki/Globoside" title="Globoside">globoside</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Globotriaosylceramide" title="Globotriaosylceramide">Globotriaosylceramide</a>: <a href="/wiki/Fabry_disease" title="Fabry disease">Fabry's disease</a></li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:1%">From <a href="/wiki/Sphingomyelin" title="Sphingomyelin">sphingomyelin</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Sphingomyelin" title="Sphingomyelin">Sphingomyelin</a>: <i>phospholipid:</i> <a href="/wiki/Niemann%E2%80%93Pick_disease" title="Niemann–Pick disease">Niemann–Pick disease</a> (<a href="/wiki/Niemann%E2%80%93Pick_disease,_SMPD1-associated" title="Niemann–Pick disease, SMPD1-associated">SMPD1-associated</a></li>
<li><a href="/wiki/Niemann%E2%80%93Pick_disease,_type_C" title="Niemann–Pick disease, type C">type C</a>)</li>
<li><a href="/wiki/Glucocerebroside" title="Glucocerebroside">Glucocerebroside</a>: <a class="mw-selflink selflink">Gaucher's disease</a></li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:1%">From <a href="/wiki/Sulfatide" title="Sulfatide">sulfatide</a><br />
(<a href="/wiki/Sulfatidosis" title="Sulfatidosis">sulfatidoses</a>
<ul>
<li><a href="/wiki/Leukodystrophy" title="Leukodystrophy">leukodystrophy</a>)</li>
</ul>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Sulfatide" title="Sulfatide">Sulfatide</a>: <a href="/wiki/Metachromatic_leukodystrophy" title="Metachromatic leukodystrophy">Metachromatic leukodystrophy</a></li>
<li><a href="/wiki/Multiple_sulfatase_deficiency" title="Multiple sulfatase deficiency">Multiple sulfatase deficiency</a></li>
<li><a href="/wiki/Galactocerebroside" title="Galactocerebroside">Galactocerebroside</a>: <a href="/wiki/Krabbe_disease" title="Krabbe disease">Krabbe disease</a></li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:1%">To <a href="/wiki/Sphingosine" title="Sphingosine">sphingosine</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Ceramide" title="Ceramide">Ceramide</a>: <a href="/wiki/Farber_disease" title="Farber disease">Farber disease</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Neuronal_ceroid_lipofuscinosis" title="Neuronal ceroid lipofuscinosis">NCL</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Infantile_neuronal_ceroid_lipofuscinosis" title="Infantile neuronal ceroid lipofuscinosis">Infantile</a></li>
<li><a href="/wiki/Jansky%E2%80%93Bielschowsky_disease" title="Jansky–Bielschowsky disease">Jansky–Bielschowsky disease</a></li>
<li><a href="/wiki/Batten_disease" title="Batten disease">Batten disease</a></li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:1%">Other</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Cerebrotendineous_xanthomatosis" title="Cerebrotendineous xanthomatosis">Cerebrotendineous xanthomatosis</a></li>
<li><a href="/wiki/Cholesteryl_ester_storage_disease" class="mw-redirect" title="Cholesteryl ester storage disease">Cholesteryl ester storage disease</a> (<a href="/wiki/Lysosomal_acid_lipase_deficiency" title="Lysosomal acid lipase deficiency">Lysosomal acid lipase deficiency</a>/<a href="/wiki/Wolman_disease" class="mw-redirect" title="Wolman disease">Wolman disease</a>)</li>
<li><a href="/wiki/Sea-blue_histiocytosis" title="Sea-blue histiocytosis">Sea-blue histiocytosis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</div>


<!-- 
NewPP limit report
Parsed by mw1233
Cached time: 20170809201004
Cache expiry: 86400
Dynamic content: true
CPU time usage: 0.284 seconds
Real time usage: 0.371 seconds
Preprocessor visited node count: 1132/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 40774/2097152 bytes
Template argument size: 969/2097152 bytes
Highest expansion depth: 10/40
Expensive parser function count: 0/500
Lua time usage: 0.123/10.000 seconds
Lua memory usage: 3.56 MB/50 MB
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  309.866      1 -total
 47.28%  146.492      1 Template:Infobox_Disease
 40.34%  124.988      1 Template:Reflist
 32.21%   99.800      1 Template:Infobox
 25.15%   77.939      5 Template:Cite_journal
  5.37%   16.652      2 Template:Navbox
  5.13%   15.905      1 Template:Lipid_storage_disorders
  4.91%   15.215      1 Template:Cite_web
  3.76%   11.656      1 Template:Comma_separated_entries
  2.25%    6.971      1 Template:Pron-en
-->
</div>